Flexible outsourcing Crozet BioPharma markets itself as an external development team that accelerates biological product pipelines, offering flexible, cost-efficient resource deployment to biopharma, vaccine developers, and non-profits. This model helps clients reduce headcount and capital outlays while accelerating development timelines.

Vaccine mastery With a track record in infectious diseases and involvement in advancing an Ebola vaccine toward licensure, Crozet BioPharma offers specialized vaccine development and regulatory acceleration capabilities.

Disease focus Adequate capability to support both infectious diseases and cancer projects, enabling cross-portfolio outsourcing for biotech firms pursuing multi-disease pipelines.

Strategic partnerships A diverse client base including public and private companies and NGOs, plus collaborators like Anivive Lifesciences for vaccine registration, signals credibility and potential joint-venture or co-development opportunities.

Mid market fit With a lean team and revenue in the 1-10M range, Crozet is well positioned to win projects from mid-sized biotechs and early-stage ventures seeking flexible development capacity without large CRO commitments.